Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors

Supplemental Table 3. Treatment-emergent Adverse Events Considered Related to Study Treatment

Preferred Term[a], n (%)	Cohort A1 (3 mg) N = 3	Cohort A2 (10 mg) N = 3	Cohort A3 (30 mg) N = 3	Cohort A4 (70 mg) N = 3
≥1 TEAE	2 (66.7)	2 (66.7)	2 (66.7)	2 (66.7)
Constipation	0 (0.0)	1 (33.3)	0 (0.0)	0 (0.0)
Dry mouth	0 (0.0)	1 (33.3)	0 (0.0)	0 (0.0)
Nausea	1 (33.3)	0 (0.0)	0 (0.0)	0 (0.0)
Fatigue	0 (0.0)	0 (0.0)	0 (0.0)	1 (33.3)
Infusion-related reaction	0 (0.0)	1 (33.3)	0 (0.0)	1 (33.3)
Increased amylase	0 (0.0)	1 (33.3)	0 (0.0)	0 (0.0)
Increased eosinophil count	0 (0.0)	0 (0.0)	1 (33.3)	0 (0.0)
Increased lipase	0 (0.0)	1 (33.3)[b]	0 (0.0)	0 (0.0)
Increased weight	1 (33.3)	0 (0.0)	0 (0.0)	0 (0.0)
Decreased white blood cell count	0 (0.0)	1 (33.3)	0 (0.0)	0 (0.0)
Decreased appetite	1 (33.3)	0 (0.0)	0 (0.0)	0 (0.0)
Myalgia	0 (0.0)	1 (33.3)	1 (33.3)	0 (0.0)
Muscular weakness	0 (0.0)	0 (0.0)	1 (33.3)	0 (0.0)
Cough	1 (33.3)	0 (0.0)	0 (0.0)	0 (0.0)
Dyspnea	0 (0.0)	1 (33.3)	0 (0.0)	0 (0.0)
Alopecia	0 (0.0)	0 (0.0)	1 (33.3)	0 (0.0)
Allergic dermatitis	0 (0.0)	0 (0.0)	1 (33.3)	0 (0.0)
PPE syndrome	0 (0.0)	0 (0.0)	1 (33.3)	0 (0.0)
Rash	0 (0.0)	0 (0.0)	0 (0.0)	1 (33.3)
Maculo-papular rash	0 (0.0)	0 (0.0)	1 (33.3)	0 (0.0)

Abbreviations: PPE, palmar-plantar erythrodysaesthesia; TEAE, treatment-emergent adverse event.

[a] TEAEs are listed by preferred term according to MedDRA Version 22.1.

[b] Although no preplanned dose modifications were allowed, 1 patient in Cohort A2 required a dose delay due to an adverse event of grade 4 lipase increase.